Eli Lilly (LLY) Stock: $20B in Deals and a New Oral GLP-1 — What’s Next?
Eli Lilly's stock has surged this year, bolstered by new drug launches and strong revenue forecasts. The company's recent developments are set to impact its future growth.
Editorial Staff
1 min read
Updated about 5 hours ago
Eli Lilly's stock opened at $1,208.37, reflecting a robust year-to-date increase of 14.4%. This performance has outpaced the broader S&P 500 index, indicating strong investor confidence.
The company’s revenue for the first quarter of 2026 is significantly supported by its GLP-1 drugs, Mounjaro and Zepbound, which together contribute nearly 65% of total revenues.
In addition to these established products, Lilly has recently launched its oral GLP-1 drug, Foundayo, which is expected to further enhance its revenue streams and market position.